Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Greg L Beilhartz

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
EMBO Molecular Medicine|August 19, 2024
An enhanced intracellular delivery platform based on a distant diphtheria toxin homolog that evades pre-existing antitoxin antibodiesShivneet K Gill, Seiji N Sugiman-Marangos, Greg L Beilhartz, et al.
Molecular Pharmaceutics|June 24, 2015
Efficient Delivery of Structurally Diverse Protein Cargo into Mammalian Cells by a Bacterial ToxinAnick Auger, Minyoung Park, Felix Nitschke, et al.
Nature Communications|December 12, 2018
Host-targeted niclosamide inhibits C. difficile virulence and prevents disease in mice without disrupting the gut microbiotaJohn Tam, Therwa Hamza, Bing Ma, et al.
The Journal of Biological Chemistry|June 13, 2008
Connection domain mutations N348I and A360V in HIV-1 reverse transcriptase enhance resistance to 3'-azido-3'-deoxythymidine through both RNase H-dependent and -independent mechanismsMaryam Ehteshami, Greg L Beilhartz, Brian J Scarth, et al.
Science Advances|September 12, 2020
Attenuated diphtheria toxin mediates siRNA deliveryAmy E Arnold, Laura J Smith, Greg L Beilhartz, et al.
The Journal of Biological Chemistry|July 9, 2011
Impact of primer-induced conformational dynamics of HIV-1 reverse transcriptase on polymerase translocation and inhibitionAnick Auger, Greg L Beilhartz, Siqi Zhu, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 4, 2020
An engineered chimeric toxin that cleaves activated mutant and wild-type RAS inhibits tumor growthVania Vidimar, Greg L Beilhartz, Minyoung Park, et al.
Molecular Pharmaceutics|September 14, 2018
Intracellular Delivery of Human Purine Nucleoside Phosphorylase by Engineered Diphtheria Toxin Rescues Function in Target CellsMinyoung Park, Xiaobai Xu, Weixian Min, et al.
Science Advances|December 14, 2020
Exploiting the diphtheria toxin internalization receptor enhances delivery of proteins to lysosomes for enzyme replacement therapySeiji N Sugiman-Marangos, Greg L Beilhartz, Xiaochu Zhao, et al.
Neuro-Oncology|June 29, 2026
Tumor-Targeted pan-RAS Inhibition as a Novel Biologic Therapy for Diffuse Midline GliomaStefanie-Grace Sbergio, Huazhu Liang, Lucy Chen, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
EMBO Molecular Medicine|August 19, 2024
An enhanced intracellular delivery platform based on a distant diphtheria toxin homolog that evades pre-existing antitoxin antibodiesShivneet K Gill, Seiji N Sugiman-Marangos, Greg L Beilhartz, et al.
Molecular Pharmaceutics|June 24, 2015
Efficient Delivery of Structurally Diverse Protein Cargo into Mammalian Cells by a Bacterial ToxinAnick Auger, Minyoung Park, Felix Nitschke, et al.
Nature Communications|December 12, 2018
Host-targeted niclosamide inhibits C. difficile virulence and prevents disease in mice without disrupting the gut microbiotaJohn Tam, Therwa Hamza, Bing Ma, et al.
The Journal of Biological Chemistry|June 13, 2008
Connection domain mutations N348I and A360V in HIV-1 reverse transcriptase enhance resistance to 3'-azido-3'-deoxythymidine through both RNase H-dependent and -independent mechanismsMaryam Ehteshami, Greg L Beilhartz, Brian J Scarth, et al.
Science Advances|September 12, 2020
Attenuated diphtheria toxin mediates siRNA deliveryAmy E Arnold, Laura J Smith, Greg L Beilhartz, et al.
The Journal of Biological Chemistry|July 9, 2011
Impact of primer-induced conformational dynamics of HIV-1 reverse transcriptase on polymerase translocation and inhibitionAnick Auger, Greg L Beilhartz, Siqi Zhu, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 4, 2020
An engineered chimeric toxin that cleaves activated mutant and wild-type RAS inhibits tumor growthVania Vidimar, Greg L Beilhartz, Minyoung Park, et al.
Molecular Pharmaceutics|September 14, 2018
Intracellular Delivery of Human Purine Nucleoside Phosphorylase by Engineered Diphtheria Toxin Rescues Function in Target CellsMinyoung Park, Xiaobai Xu, Weixian Min, et al.
Science Advances|December 14, 2020
Exploiting the diphtheria toxin internalization receptor enhances delivery of proteins to lysosomes for enzyme replacement therapySeiji N Sugiman-Marangos, Greg L Beilhartz, Xiaochu Zhao, et al.
Neuro-Oncology|June 29, 2026
Tumor-Targeted pan-RAS Inhibition as a Novel Biologic Therapy for Diffuse Midline GliomaStefanie-Grace Sbergio, Huazhu Liang, Lucy Chen, et al.
Pageof 3